VVOSVivos Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Vivos Therapeutics, Inc. against Surgical & Medical Instruments & Apparatus — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VVOSThis | $4M#7 | — | — | 0.2x#2 | 16.0%#7 | -90.1%#12 | -114.1%#5 | — | -780.5%#9 | 4#3 | -94.9%#14 | — |
| NVNO | $6M#1 | — | 0.3x#5 | 198.0x#15 | -83.3%#11 | 10.8%#3 | -66891.8%#14 | -94.2%#6 | — | — | -71.3%#6 | — |
| SNOA | $6M#2 | — | 0.9x#9 | 0.3x#5 | 36.7%#3 | -8.2%#8 | -12.6%#1 | 0.0%#2 | -174.4%#5 | — | -70.3%#5 | — |
| CODX | $6M#4 | — | 0.5x#7 | 9.5x#13 | -84.1%#12 | -23.7%#11 | -8058.8%#12 | -369.7%#10 | -389.5%#7 | — | -92.5%#12 | — |
| INBS | $6M#3 | — | 1.1x#10 | 1.4x#10 | 38.1%#2 | -17.6%#10 | -299.1%#6 | -225.6%#9 | -397.9%#8 | — | -85.9%#8 | — |
| OSRH | $4M#5 | 0.6x#5 | — | 1.4x#9 | -17.7%#9 | -162.0%#13 | -631.0%#8 | — | — | 2#6 | -84.0%#7 | — |
| BJDX | $4M#6 | — | 0.4x#6 | 14.6x#14 | — | 11.3%#2 | -2791.9%#11 | -72.7%#5 | — | — | -86.6%#9 | — |
| TNON | $3M#8 | 0.3x#3 | — | 0.7x#7 | 20.4%#6 | 8.2%#6 | -324.3%#7 | — | — | — | -89.7%#10 | — |
| NXGL | $2M#9 | — | 0.5x#8 | 0.2x#3 | 31.5%#4 | 8.6%#4 | -29.3%#2 | -60.6%#3 | -68.1%#2 | 4#3 | -90.2%#11 | — |
| VTAK | $2M#11 | — | 0.1x#3 | 2.8x#11 | 95.0%#1 | -3.2%#7 | -2581.6%#10 | -97.8%#7 | -79.7%#4 | 5#1 | -94.1%#13 | — |
| OSRHW | $2M#12 | 0.3x#4 | — | 0.7x#8 | -17.7%#9 | -162.0%#13 | -631.0%#8 | — | — | 2#6 | 24.5%#2 | — |
| IVF | $2M#10 | 0.0x#2 | 0.1x#4 | 0.3x#6 | 4.7%#8 | 157.6%#1 | -105.8%#4 | 141.4%#1 | -44.8%#1 | 5#1 | -97.5%#16 | — |
| SKYAW | $1M#13 | — | 0.0x#1 | 6.2x#12 | — | -2938.9%#16 | -132145.5%#15 | -179.6%#8 | -181.9%#6 | — | -13.8%#4 | — |
| MCAGR | $178989#14 | — | — | — | — | -15.1%#9 | — | — | — | — | -7.7%#3 | — |
| NVACW | $21985#16 | 0.0x#1 | — | 0.2x#4 | — | -288.1%#15 | -27706.0%#13 | — | — | — | 55.8%#1 | — |
| NXGLW | $121846#15 | — | 0.0x#2 | 0.0x#1 | 31.5%#4 | 8.6%#4 | -29.3%#2 | -60.6%#3 | -68.1%#2 | 4#3 | -95.3%#15 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3841). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice